EP1169028A1 - Treatment of hiatial hernia - Google Patents

Treatment of hiatial hernia

Info

Publication number
EP1169028A1
EP1169028A1 EP00918070A EP00918070A EP1169028A1 EP 1169028 A1 EP1169028 A1 EP 1169028A1 EP 00918070 A EP00918070 A EP 00918070A EP 00918070 A EP00918070 A EP 00918070A EP 1169028 A1 EP1169028 A1 EP 1169028A1
Authority
EP
European Patent Office
Prior art keywords
compound
formula
cyclobutyl
chlorophenyl
methylbutylamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00918070A
Other languages
German (de)
French (fr)
Inventor
Carl M. Mendel
Timothy B. Seaton
Steve P. Weinstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Knoll GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll GmbH filed Critical Knoll GmbH
Publication of EP1169028A1 publication Critical patent/EP1169028A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Definitions

  • This invention relates to a method of treating hiatial hernias and reflux esophagitis.
  • R 1 and R 2 are independently H or methyl, is administered in conjunction with a pharmaceutically acceptable diluent or carrier to a human in need thereof.
  • a preferred compound of formula I is N,N-dimethyl-1-[1-(4- chlorophenyl)cyclobutyl]-3-methylbutylamine or a salt thereof, for example the hydrochloride salt.
  • a preferred form of this hydrochloride is its monohydrate.
  • N, N-dimethyl-1 -[1-(4-chlorophenyl)cyclobutyl]-3- methylbutylamine hydrochloride in the treatment of obesity is described in published PCT application WO90/06110.
  • a particularly preferred form of this compound is N, N-dimethyl-1 -[1 -(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate (sibutramine hydrochloride) which is described in European Patent Number 230742.
  • the enantiomers may be resolved by methods known to those skilled in the art, for example by formation of diastereoisomeric salts or complexes which may be separated, for example, by crystallisation; via formation of diastereoisomeric derivatives which may be separated, for example, by crystallisation, gas-liquid or liquid chromatography; selective reaction of one enantiomer with an enantiomer- specific reagent, for example enzymatic oxidation or reduction, followed by separation of the modified and unmodified enantiomers; or gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support, for example silica with a bound chiral ligand or in the presence of a chiral solvent.
  • enantiomers may be synthesised by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer to the other by asymmetric transformation.
  • Preferred compounds of formula I are N ! N-dimethyl-1-[1-(4-chlorophenyl)- cyclobutyl]-3-methylbutylamine, N- ⁇ 1 -[1 -(4-chlorophenyl)cyclobutyl]-3- methylbutyl ⁇ -N- methylamine, and 1-[1-(4-chlorophenyl)cyclobutyl]-3- methylbutylamine including racemates, individual enantiomers and mixtures thereof, and pharmaceutically acceptable salts thereof.
  • the individual enantiomers can be prepared by enantioselective synthesis from optically active precursors, or by resolving the racemic compound which can be prepared as described above.
  • Enantiomers of secondary amines of the formula I can also be prepared by preparing the racemate of the corresponding primary amine, resolving the latter into the individual enantiomers, and then converting the optically pure primary amine enantiomer into the required secondary amine by methods described in British Patent Specification 2098602.
  • the hydrochloride salts are preferred in each case, but the free bases and other pharmaceutically acceptable salts are also suitable.
  • the compound of formula I may be administered in any of the known pharmaceutical dosage forms.
  • the amount of the compound to be administered will depend on a number of factors including the age of the patient, the severity of the condition and the past medical history of the patient and always lies within the sound discretion of the administering physician but it is generally envisaged that the dosage of the compound to be administered will be in the range 0.1 to 50 mg preferably 1 to 30 mg per day given in one or more doses.
  • Oral dosage forms are the preferred compositions for use in the present invention and these are the known pharmaceutical forms for such administration, for example tablets, capsules, granules, syrups and aqueous or oil suspensions.
  • the excipients used in the preparation of these compositions are the excipients known in the pharmacist's art.
  • Tablets may be prepared from a mixture of the active compound with fillers, for example calcium phosphate; disintegrating agents, for example maize starch; lubricating agents, for example magnesium stearate; binders, for example microcrystalline cellulose or polyvinylpyrrolidone and other optional ingredients known in the art to permit tableting the mixture by known methods.
  • the tablets may, if desired, be coated using known methods and excipients which may include enteric coating using for example hydroxypropylmethylcellulose phthalate.
  • the tablets may be formulated in a manner known to those skilled in the art so as to give a sustained release of the compounds of the present invention.
  • Such tablets may, if desired, be provided with enteric coatings by known methods, for example by the use of cellulose acetate phthalate.
  • capsules for example hard or soft gelatin capsules, containing the active compound with or without added excipients, may be prepared by known methods and, if desired, provided with enteric coatings in a known manner. The contents of the capsule may be formulated using known methods so as to give sustained release of the active compound.
  • the tablets and capsules may conveniently each contain 1 to 50 mg of the active compound.
  • Other dosage forms for oral administration include, for example, aqueous suspensions containing the active compound in an aqueous medium in the presence of a non-toxic suspending agent such as sodium carboxy- methylcellulose, and oily suspensions containing a compound of the present invention in a suitable vegetable oil, for example arachis oil.
  • the active compound may be formulated into granules with or without additional excipients.
  • the granules may be ingested directly by the patient or they may be added to a suitable liquid carrier (for example, water) before ingestion.
  • the granules may contain disintegrants, eg an effervescent couple formed from an acid and a carbonate or bicarbonate salt to facilitate dispersion in the liquid medium.
  • the therapeutically active compounds of formula I may be formulated into a composition which the patient retains in his mouth so that the active compound is administered through the mucosa of the mouth.
  • Dosage forms suitable for rectal administration are the known pharmaceutical forms for such administration, for example, suppositories with cocoa butter or polyethylene glycol bases.
  • Dosage forms suitable for parenterai administration are the known pharmaceutical forms for such administration, for example sterile suspensions or sterile solutions in a suitable solvent.
  • Dosage forms for topical administration may comprise a matrix in which the pharmacologically active compounds of the present invention are dispersed so that the compounds are held in contact with the skin in order to administer the compounds transdermally.
  • a suitable transdermal composition may be prepared by mixing the pharmaceutically active compound with a topical vehicle, such as a mineral oil, petrolatum and/or a wax, e.g. paraffin wax or beeswax, together with a potential transdermal accelerant such as dimethyl sulphoxide or propylene glycol.
  • the active compounds may be dispersed in a pharmaceutically acceptable cream, gel or ointment base.
  • the amount of active compound contained in a topical formulation should be such that a therapeutically effective amount of the compound is delivered during the period of time for which the topical formulation is intended to be on the skin.
  • the therapeutically active compound of formula I may be formulated into a composition which is dispersed as an aerosol into the patients oral or nasal cavity.
  • Such aerosols may be administered from a pump pack or from a pressurised pack containing a volatile propellant.
  • the therapeutically active compounds of formula I used in the method of the present invention may also be administered by continuous infusion either from an external source, for example by intravenous infusion or from a source of the compound placed within the body.
  • Internal sources include implanted reservoirs containing the compound to be infused which is continuously released for example by osmosis and implants which may be (a) liquid such as an oily suspension of the compound to be infused for example in the form of a very sparingly water-soluble derivative such as a dodecanoate salt or a lipophilic ester or (b) solid in the form of an implanted support, for example of a synthetic resin or waxy material, for the compound to be infused.
  • the support may be a single body containing all the compound or a series of several bodies each containing part of the compound to be delivered.
  • the amount of active compound present in an internal source should be such that a therapeutically effective amount of the compound is delivered over a long period of time.
  • the compounds of the present invention may be beneficial to use in the form of particles of very small size, for example as obtained by fluid energy milling.
  • the active compound may, if desired, be associated with other compatible pharmacologically active ingredients.
  • the invention further provides the use of compounds of formula I in the manufacture of a medicament for treating hiatial hernias.
  • the invention further provides a pharmaceutical composition for treating hiatial hernias, comprising a compound of formula I in conjunction with a pharmaceutically acceptable diluent or carrier.
  • Monoamine reuptake inhibitors have been used to treat certain of the disorders described in the present invention.
  • these compounds are known to suffer from a number of disadvantages. Firstly such compounds are not effective in all patients. Secondly where the compounds are effective they may not provide a complete cure of the disorder. Thirdly, there are many undesirable side-effects known with this type of compound. Such side-effects include nausea, sexual dysfunction, light headedness, somnolence, sweating, tremor, dry mouth, asthenia, insomnia, diarrhoea, headache, vomiting, anxiety, drowsiness, dizziness, fever, rash or allergic reactions, arthralgia, myalgia, convulsions, hypomania and mania.
  • noradenaline-selective reuptake inhibitors e.g.
  • the efficacy of compounds of formula I in treating hiatial hernias is demonstrable through clinical trials in a relevant population set. Improvement in the conditions is related to weight loss.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A compound of formula (I), or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example N, N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is used for treating hiatial hernias and reflux esophagitis.

Description

Treatment of Hiatial Hernia
This invention relates to a method of treating hiatial hernias and reflux esophagitis.
According to the present invention there is provided a method of treating hiatial hernias, in which a therapeutically effective amount of a compound of formula I
CH-
including enantiomers and pharmaceutically acceptable salts thereof, in which R1 and R2 are independently H or methyl, is administered in conjunction with a pharmaceutically acceptable diluent or carrier to a human in need thereof.
A preferred compound of formula I is N,N-dimethyl-1-[1-(4- chlorophenyl)cyclobutyl]-3-methylbutylamine or a salt thereof, for example the hydrochloride salt. A preferred form of this hydrochloride is its monohydrate.
The preparation and use of compounds of formula I, such asjsi N- dimethyl-1 -[1 -(4-chlorophenyl)cyclobutyl]-3-methylbutylamine, N-{1 -[1 -(4- chlorophenyl)-cyclobutyl]-3-methylbutyl}-N-methylamine, and 1-[1-(4- chlorophenyl)-cyclobutyl]-3-methylbutyiamine and salts thereof, in the treatment of depression is described in British Patent Specification 2098602 and US Patent 4,522,328. The use of compounds of formula I such asJvllN-dimethyl-1-[1-(4- chlorophenyl)cyclobutyl]-3-methylbutylamine and salts thereof in the treatment of Parkinson's disease is described in published PCT application WO 88/06444. The use of N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine and salts thereof in the treatment of cerebral function disorders is described in US Patent 4,939,175. The use of N, N-dimethyl-1 -[1-(4-chlorophenyl)cyclobutyl]-3- methylbutylamine hydrochloride in the treatment of obesity is described in published PCT application WO90/06110. A particularly preferred form of this compound is N, N-dimethyl-1 -[1 -(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate (sibutramine hydrochloride) which is described in European Patent Number 230742. The use of N, N-dimethyl-1 -[1 -(4- chlorophenyl)cyclobutyl]-3-methylbutylamine and salts thereof for improving the glucose tolerance of humans having Impaired Glucose Tolerance or Non-Insulin Dependent Diabetes Mellitus is described in published PCT application WO95/20949.
It will be appreciated by those skilled in the art that compounds of formula I contain a chiral centre. When a compound of formula I contains a single chiral centre it may exist in two enantiomeric forms. The present invention includes the use of the individual enantiomers and mixtures of the enantiomers. The enantiomers may be resolved by methods known to those skilled in the art, for example by formation of diastereoisomeric salts or complexes which may be separated, for example, by crystallisation; via formation of diastereoisomeric derivatives which may be separated, for example, by crystallisation, gas-liquid or liquid chromatography; selective reaction of one enantiomer with an enantiomer- specific reagent, for example enzymatic oxidation or reduction, followed by separation of the modified and unmodified enantiomers; or gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support, for example silica with a bound chiral ligand or in the presence of a chiral solvent. It will be appreciated that where the desired enantiomer is converted into another chemical entity by one of the separation procedures described above, a further step is required to liberate the desired enantiomeric form. Alternatively, specific enantiomers may be synthesised by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer to the other by asymmetric transformation.
Preferred compounds of formula I are N!N-dimethyl-1-[1-(4-chlorophenyl)- cyclobutyl]-3-methylbutylamine, N-{1 -[1 -(4-chlorophenyl)cyclobutyl]-3- methylbutyl}-N- methylamine, and 1-[1-(4-chlorophenyl)cyclobutyl]-3- methylbutylamine including racemates, individual enantiomers and mixtures thereof, and pharmaceutically acceptable salts thereof.
The individual enantiomers can be prepared by enantioselective synthesis from optically active precursors, or by resolving the racemic compound which can be prepared as described above. Enantiomers of secondary amines of the formula I can also be prepared by preparing the racemate of the corresponding primary amine, resolving the latter into the individual enantiomers, and then converting the optically pure primary amine enantiomer into the required secondary amine by methods described in British Patent Specification 2098602.
Specific examples of compounds of formula I are:
(+)-N-[1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N-methylamine; (-)-N-{1-[1-(4-chlorophenyl)cyclobutyl-3-methylbutyl}-N-methylamine; (+)-1 -[1 -(4-chlorophenyl)cyclobutyl]-3-methylbutylamine; (-)-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine; (+)-N-{1 -[1 -(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N-N-dimethylamine; (-)-N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N-N-dimethylamine.
The hydrochloride salts are preferred in each case, but the free bases and other pharmaceutically acceptable salts are also suitable. The compound of formula I may be administered in any of the known pharmaceutical dosage forms. The amount of the compound to be administered will depend on a number of factors including the age of the patient, the severity of the condition and the past medical history of the patient and always lies within the sound discretion of the administering physician but it is generally envisaged that the dosage of the compound to be administered will be in the range 0.1 to 50 mg preferably 1 to 30 mg per day given in one or more doses.
Oral dosage forms are the preferred compositions for use in the present invention and these are the known pharmaceutical forms for such administration, for example tablets, capsules, granules, syrups and aqueous or oil suspensions. The excipients used in the preparation of these compositions are the excipients known in the pharmacist's art. Tablets may be prepared from a mixture of the active compound with fillers, for example calcium phosphate; disintegrating agents, for example maize starch; lubricating agents, for example magnesium stearate; binders, for example microcrystalline cellulose or polyvinylpyrrolidone and other optional ingredients known in the art to permit tableting the mixture by known methods. The tablets may, if desired, be coated using known methods and excipients which may include enteric coating using for example hydroxypropylmethylcellulose phthalate. The tablets may be formulated in a manner known to those skilled in the art so as to give a sustained release of the compounds of the present invention. Such tablets may, if desired, be provided with enteric coatings by known methods, for example by the use of cellulose acetate phthalate. Similarly, capsules, for example hard or soft gelatin capsules, containing the active compound with or without added excipients, may be prepared by known methods and, if desired, provided with enteric coatings in a known manner. The contents of the capsule may be formulated using known methods so as to give sustained release of the active compound. The tablets and capsules may conveniently each contain 1 to 50 mg of the active compound. Other dosage forms for oral administration include, for example, aqueous suspensions containing the active compound in an aqueous medium in the presence of a non-toxic suspending agent such as sodium carboxy- methylcellulose, and oily suspensions containing a compound of the present invention in a suitable vegetable oil, for example arachis oil. The active compound may be formulated into granules with or without additional excipients. The granules may be ingested directly by the patient or they may be added to a suitable liquid carrier (for example, water) before ingestion. The granules may contain disintegrants, eg an effervescent couple formed from an acid and a carbonate or bicarbonate salt to facilitate dispersion in the liquid medium.
The therapeutically active compounds of formula I may be formulated into a composition which the patient retains in his mouth so that the active compound is administered through the mucosa of the mouth.
Dosage forms suitable for rectal administration are the known pharmaceutical forms for such administration, for example, suppositories with cocoa butter or polyethylene glycol bases.
Dosage forms suitable for parenterai administration are the known pharmaceutical forms for such administration, for example sterile suspensions or sterile solutions in a suitable solvent.
Dosage forms for topical administration may comprise a matrix in which the pharmacologically active compounds of the present invention are dispersed so that the compounds are held in contact with the skin in order to administer the compounds transdermally. A suitable transdermal composition may be prepared by mixing the pharmaceutically active compound with a topical vehicle, such as a mineral oil, petrolatum and/or a wax, e.g. paraffin wax or beeswax, together with a potential transdermal accelerant such as dimethyl sulphoxide or propylene glycol. Alternatively the active compounds may be dispersed in a pharmaceutically acceptable cream, gel or ointment base. The amount of active compound contained in a topical formulation should be such that a therapeutically effective amount of the compound is delivered during the period of time for which the topical formulation is intended to be on the skin.
The therapeutically active compound of formula I may be formulated into a composition which is dispersed as an aerosol into the patients oral or nasal cavity. Such aerosols may be administered from a pump pack or from a pressurised pack containing a volatile propellant.
The therapeutically active compounds of formula I used in the method of the present invention may also be administered by continuous infusion either from an external source, for example by intravenous infusion or from a source of the compound placed within the body. Internal sources include implanted reservoirs containing the compound to be infused which is continuously released for example by osmosis and implants which may be (a) liquid such as an oily suspension of the compound to be infused for example in the form of a very sparingly water-soluble derivative such as a dodecanoate salt or a lipophilic ester or (b) solid in the form of an implanted support, for example of a synthetic resin or waxy material, for the compound to be infused. The support may be a single body containing all the compound or a series of several bodies each containing part of the compound to be delivered. The amount of active compound present in an internal source should be such that a therapeutically effective amount of the compound is delivered over a long period of time.
In some formulations it may be beneficial to use the compounds of the present invention in the form of particles of very small size, for example as obtained by fluid energy milling. In the compositions of the present invention the active compound may, if desired, be associated with other compatible pharmacologically active ingredients.
The invention further provides the use of compounds of formula I in the manufacture of a medicament for treating hiatial hernias.
In another aspect, the invention further provides a pharmaceutical composition for treating hiatial hernias, comprising a compound of formula I in conjunction with a pharmaceutically acceptable diluent or carrier.
Monoamine reuptake inhibitors have been used to treat certain of the disorders described in the present invention. However, these compounds are known to suffer from a number of disadvantages. Firstly such compounds are not effective in all patients. Secondly where the compounds are effective they may not provide a complete cure of the disorder. Thirdly, there are many undesirable side-effects known with this type of compound. Such side-effects include nausea, sexual dysfunction, light headedness, somnolence, sweating, tremor, dry mouth, asthenia, insomnia, diarrhoea, headache, vomiting, anxiety, drowsiness, dizziness, fever, rash or allergic reactions, arthralgia, myalgia, convulsions, hypomania and mania.
Sibutramine (Formula I, R-i = CH3 R2 = CH3) has a pharmacological profile which is unique amongst monoamine reuptake inhibitors. Through its pharmacologically active metabolites, (metabolite 1 , R-i = H, R2 = CH3 in Formula I and metabolite 2, R<\ = H, R2 = H in Formula I) sibutramine inhibits the reuptake of all three monoamines differentiating it from serotonin (5-HT)-selective reuptake inhibitors, e.g. fluoxetine, noradenaline-selective reuptake inhibitors, e.g. desipramine, dopamine-selective reuptake inhibitors, e.g. bupropion, and serotonin-noradenaline reuptake inhibitors, e.g. venlafaxine (Table 1). It is this unique combination of pharmacological actions which renders sibutramine, and the other compounds of formula I, efficacious in the treatment of hiatial hernias and reflux esophagitis.
The assays below are performed in a similar manner to those described in WO98/41528.
TABLE
Comparison of the in vitro monoamine reuptake inhibition profiles of Examples 1 and 2, and various reference monoamine reuptake inhibitors in rat brain tissue
The results are the means of >3 separate determinations
Example 1 R-i = H R2 = CH3 in Formula I
Example 2 R1 = H R2 = H in Formula The efficacy of compounds of formula I in treating hiatial hernias is demonstrable through clinical trials in a relevant population set. Improvement in the conditions is related to weight loss.
The invention has been described with reference to various specific embodiments. However, many variations and modifications may be made while remaining within the scope and spirit of the invention.

Claims

Claims
1. A method of treating hiatial hernias or reflux esophagitis comprising administering to a human in need thereof a therapeutically effective amount of a compound of formula I
CH-
including enantiomers and pharmaceutically acceptable salts thereof in which R and R2 are independently H or methyl, in conjunction with a pharmaceutically acceptable diluent or carrier.
2. A method as claimed in claim 1 wherein the compound of formula I isN.N- dimethyl-1 -[1 -(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride.
3. A method as claimed in claim 1 wherein the compound of formula I is
N, N-dimethyl-1 -[1 -(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride in the form of its monohydrate.
4. A method as claimed in claim 1 wherein the compound of formula 1 is (+) N-[1 -[1 -(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N-methylamine.
5. A method as claimed in claim 1 wherein the compound of formula 1 is (-)-N-{1-[1-(4-chlorophenyl)cyclobutyl-3-methylbutyl}-N-methylamine.
6. A method as claimed in claim 1 wherein the compound of formula 1 is (+)-1 -[1 -(4-chlorophenyl)cyclobutyl]-3-methylbutylamine.
7. A method as claimed in claim 1 wherein the compound of formula 1 is (-)-1 -[1 -(4-chlorophenyl)cyclobutyl]-3-methylbutylamine.
8 A method as claimed in claim 1 wherein the compound of formula 1 is (+)-N-{1 -[1 -(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N-N-dimethylamine.
9. The method as claimed in claim 1 wherein the compound of formula I is (-)-N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methyibutyl}-N-N-dimethylamine.
10. The method as claimed in claim 1 wherein the compound of formula I is (+)-N-{1-[1-(4-chlorophenyl)cyclobutyl-3-methylbutyl}-N-methylamine.
11. The method as claimed in claim 1 wherein the compound of formula I is (±)-1 -[1 -(4-chlorophenyl)cyclobutyl]-3-methylbutylamine.
12. The method as claimed in claim 1 wherein the compound of formula I is (±)-N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N-N-dimethylamine.
13. The use of a compound of formula I
CH-
including enantiomers and pharmaceutically acceptable salts thereof in which R^ and R2 are independently H or methyl, in the manufacture of a medicament for treating hiatial hernias and reflux esophagitis.
14. The use as claimed in claim 13 in which the compound of formula I is N, N-dimethyl-1 -[1 -(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride.
15. The use as claimed in claim 13 in which the compound of formula I is N, N-dimethyl-1 -[1 -(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate.
16. A pharmaceutical composition for treating hiatial hernias or reflux esophagitis, comprising a therapeutically effective amount of a compound of formula I
CH,
including enantiomers and pharmaceutically acceptable salts thereof in which R and R2 are independently H or methyl, in conjunction with a pharmaceutically acceptable diluent or carrier.
17. A pharmaceutical composition as claimed in claim 16 in which the compound of formula I is N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3- methylbutylamine hydrochloride.
18. A pharmaceutical composition as claimed in claim 16 in which the compound of formula I is N, -dimethyl-1 -[1-(4-chlorophenyl)cyclobutyl]-3- methylbutylamine hydrochloride monohydrate.
EP00918070A 1999-03-19 2000-03-17 Treatment of hiatial hernia Withdrawn EP1169028A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12511699P 1999-03-19 1999-03-19
US125116P 1999-03-19
PCT/US2000/007112 WO2000056307A1 (en) 1999-03-19 2000-03-17 Treatment of hiatial hernia

Publications (1)

Publication Number Publication Date
EP1169028A1 true EP1169028A1 (en) 2002-01-09

Family

ID=22418261

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00918070A Withdrawn EP1169028A1 (en) 1999-03-19 2000-03-17 Treatment of hiatial hernia

Country Status (20)

Country Link
EP (1) EP1169028A1 (en)
JP (1) JP2002539249A (en)
KR (1) KR20030006909A (en)
CN (1) CN1376061A (en)
AU (1) AU3894400A (en)
BG (1) BG106000A (en)
BR (1) BR0009160A (en)
CA (1) CA2367035A1 (en)
CZ (1) CZ20013279A3 (en)
HK (1) HK1044703A1 (en)
HU (1) HUP0200498A2 (en)
IL (1) IL145242A0 (en)
MX (1) MXPA01009463A (en)
NO (1) NO20014476L (en)
NZ (1) NZ514013A (en)
PL (1) PL351081A1 (en)
SK (1) SK13392001A3 (en)
TR (1) TR200102700T2 (en)
WO (1) WO2000056307A1 (en)
ZA (1) ZA200107679B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103006833B (en) * 2012-12-31 2014-02-12 代凤玲 Medicine for hiatus hernia postoperative rehabilitation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2675573B2 (en) * 1988-03-31 1997-11-12 科研製薬株式会社 Brain function improver

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0056307A1 *

Also Published As

Publication number Publication date
IL145242A0 (en) 2002-06-30
ZA200107679B (en) 2003-06-18
CZ20013279A3 (en) 2002-07-17
NZ514013A (en) 2001-09-28
BG106000A (en) 2002-06-28
MXPA01009463A (en) 2004-03-19
CN1376061A (en) 2002-10-23
NO20014476D0 (en) 2001-09-14
JP2002539249A (en) 2002-11-19
HK1044703A1 (en) 2002-11-01
CA2367035A1 (en) 2000-09-28
KR20030006909A (en) 2003-01-23
SK13392001A3 (en) 2002-04-04
AU3894400A (en) 2000-10-09
TR200102700T2 (en) 2002-04-22
WO2000056307A1 (en) 2000-09-28
NO20014476L (en) 2001-10-29
HUP0200498A2 (en) 2002-08-28
BR0009160A (en) 2002-01-29
PL351081A1 (en) 2003-03-10

Similar Documents

Publication Publication Date Title
AU773188C (en) Method of treating eating disorders
US6376553B1 (en) Treatment of pain
WO2000056309A1 (en) Method of treating sexual dysfunction
WO2000056318A1 (en) Treatment of neuropathic pain or fibromyalgia
WO2000056149A1 (en) Method of treating anxiety disorders
US6376551B1 (en) Treatment of chronic fatigue syndrome
US6441046B1 (en) Control of metabolism
WO2000056320A1 (en) Treatment of menstrual function
US6380260B1 (en) Treatment to lower platelet adhesiveness
US6232347B1 (en) Treatment of osteoarthritis
US6803387B1 (en) Treatment of neuropathic pain or fibromyalgia
AU773490B2 (en) Treatment of osteoarthritis
WO2000056150A1 (en) Treatment of premenstrual syndrome
US6365632B1 (en) Treatment of orthostatic hypotension
WO2000056148A1 (en) Treatment of pharmacology of drug misuse and other addictive disorders
US6288125B1 (en) Treatment of hiatial hernia
CA2366652A1 (en) Treatment of pulmonary hypertension
WO2000056151A1 (en) Method of treating obsessive-compulsive disorder
US20020132856A1 (en) Treatment of premenstrual syndrome
US20030013735A1 (en) Weight loss after pregnancy
EP1169028A1 (en) Treatment of hiatial hernia
WO2000056308A1 (en) Prevention of cardiovascular disease
WO2000056323A1 (en) Treatment of certain cancers associated with weight gain
WO2000056317A1 (en) Weight loss after pregnancy

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010919

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: LT PAYMENT 20010919;LV PAYMENT 20010919;RO PAYMENT 20010919;SI PAYMENT 20010919

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20031001

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1044703

Country of ref document: HK